Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LNCB74
- Development stage
- Phase 1
- Lead developer
- NextCure
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
LNCB74 is an antibody-drug conjugate (ADC) that targets B7-H4, a protein highly expressed on multiple solid tumors, including breast, ovarian, endometrial, biliary tract, and non-small cell lung cancers. The drug consists of a B7-H4-specific antibody conjugated to the microtubule-disrupting payload monomethyl auristatin E (MMAE) via a glucuronidase-cleavable linker using LigaChem Biosciences’ ConjuAll technology. This site-specific linkage increases stability in circulation and enables selective release of the cytotoxic payload within tumor cells while minimizing off-target toxicity. LNCB74 incorporates an Fc region mutation to reduce uptake by immune cells expressing Fc receptors. Preclinical studies have demonstrated potent antitumor activity and favorable safety profiles in animal models. As of early 2025, LNCB74 is in Phase 1 clinical trials for advanced solid tumors.
- Other names
- B7-H4 ADCB-7-H4 ADCB 7-H4 ADC
02
Targets
VTCN1 (V-set domain containing T cell activation inhibitor 1)
Beyond the preview
Go deeper on LNCB74.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LNCB74.